Subject
Pharmacology (medical),Pharmacology
Reference9 articles.
1. Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial;Heijerman;Lancet,2019
2. Elexacaftor-Tezacaftor-Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele;Middleton;N Engl J Med,2019
3. European Medicines Agency. Summary of Product Characteristics - KAFTRIO.: European Medicines Agency; 2020. Contract No.: EMEA/H/C/005269.
4. Phase 1 Study to Assess the Safety and Pharmacokinetics of Elexacaftor/Tezacaftor/Ivacaftor in Subjects Without Cystic Fibrosis With Moderate Hepatic Impairment;Viswanathan;Eur J Drug Metab Pharmacokinet,2022
5. A Quantitative Method for the Analysis of Ivacaftor, Hydroxymethyl Ivacaftor, Ivacaftor Carboxylate, Lumacaftor, and Tezacaftor in Plasma and Sputum Using LC-MS/MS and Its Clinical Applicability;Vonk;Ther Drug Monit,2021